Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dianthus Therapeutics (DNTH) and Biogen (BIIB) with bullish sentiments.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Dianthus Therapeutics (DNTH)
In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on Dianthus Therapeutics. The company’s shares closed last Friday at $82.74.
According to TipRanks.com, Deschner is a 5-star analyst with an average return of
Currently, the analyst consensus on Dianthus Therapeutics is a Strong Buy with an average price target of $130.00, implying a 67.9% upside from current levels. In a report issued on June 10, William Blair also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Biogen (BIIB)
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Biogen, with a price target of $221.00. The company’s shares closed last Friday at $199.92.
According to TipRanks.com, Syed is a 1-star analyst with an average return of
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $221.14, implying a 10.3% upside from current levels. In a report issued on June 8, Needham also upgraded the stock to Buy with a $255.00 price target.
Read More on DNTH:
